Notice Regarding Result of Tender Offer for Common Shares of DNA Chip Research Inc.

Mitsui Chemicals, Inc. (Head Office: Chuo, Tokyo; President & CEO: HASHIMOTO Osamu; securities code: 4183; “Mitsui Chemicals”) announced on February 4, 2025, its decision to make a tender offer to acquire the common shares in DNA Chip Research Inc. (Head Office: Kawasaki, Kanagawa; President & CEO: MATOBA Ryo; securities code: 2397; “DNA Chip Research”), which is listed on the Tokyo Stock Exchange Standard Market. The tender offer commenced on February 5, 2025, and was completed on April 7, 2025.

Mitsui Chemicals has today announced that the total number of share certificates, etc. tendered in the tender offer (henceforth, “Tendered Share Certificates, etc.”) was exceeded the minimum number of share certificates to be purchased. Accordingly, Mitsui Chemicals will purchase all of the Tendered Share Certificates, etc., as described in ”Notice Regarding Commencement of Tender Offer for Common Shares of DNA Chip Research Inc.(Securities Code 2397)”.

In pursuing portfolio reform as a basic strategy for achieving its VISION 2030 Long-Term Business Plan, Mitsui Chemicals aims to become a truly global specialty company by leaning on the two key pillars of a high-growth, high-profitability global specialty chemicals business and a sustainable green chemicals business centered on competitive derivatives. The company’s Life & Healthcare Solutions business – which the company is positioning as an area of growth – is an important part of this plan, offering earnings with minimal volatility. The business achieved reliable growth throughout the COVID-19 pandemic and continues to do so today.

Going forward, Mitsui Chemicals intends to continue to bolster its Life & Healthcare Solutions business by turning its medical sector – which handles oral care, orthopedics, and testing and diagnosis – into a third pillar of earnings for this business, alongside the life care sector, which is focused on vision care materials, and the wellness sector, which is focused on agrochemicals. To achieve this, the company is actively investing resources and also acquiring business foundations in new areas by conducting M&A and forming external partnerships.

A business and capital partnership first formed with DNA Chip Research in 2023 and second strengthened in 2024 has seen Mitsui Chemicals develop and pursue new business themes, as well as consider the growth of both companies’ testing and diagnosis businesses. Now, with sights set on achieving further growth for both companies, Mitsui Chemicals has carried out a tender offer through which it intends to acquire DNA Chip Research as a wholly owned subsidiary. Mitsui Chemicals expects that this will both facilitate the efficient and proactive investment of Mitsui Chemicals’ management resources and enable unified, closely coordinated business management between the two companies.

The tender offer set a condition that if the total number of Tendered Share Certificates, etc. was less than the minimum number of share certificates to be purchased (3,119,000 shares), the tender offeror would purchase none of the Tendered Share Certificates, etc. However, because the total number of Tendered Share Certificates, etc. (3,669,512 shares) was exceeded the minimum number of share certificates to be purchased (3,119,000 shares), the tender offeror will purchase all of the Tendered Share Certificates, etc., as described in ”Notice Regarding Commencement of Tender Offer for Common Shares of DNA Chip Research Inc.(Securities Code 2397)”

There are no changes in the policies after the tender offer and future prospects from the details provided in the release titled “Notice Regarding Commencement of Tender Offer for Common Shares of DNA Chip Research Inc. (Securities Code: 2397)” published on February 4, 2025.

In order to become the sole shareholder of DNA Chip Research, Mitsui Chemicals intends to carry out a series of procedures for taking the shares in DNA Chip Research private (hereinafter the “Squeeze-Out Procedures”). Shares in DNA Chip Research are currently listed on the Tokyo Stock Exchange Standard Market. However, if the Squeeze-Out Procedures is carried out, these shares will be delisted through the prescribed procedure in accordance with the stock delisting criteria of the Tokyo Stock Exchange. After delisting, shares in DNA Chip Research will no longer be able to be traded on the Tokyo Stock Exchange Standard Market. DNA Chip Research intends to announce any relevant procedures going forward promptly once they have been determined.

For more information, see “Notice Regarding Result of Tender Offer for Common Shares of DNA Chip Research Inc. (Securities Code 2397)” (April 8, 2025).